SCHEMBL5934166

SCHEMBL5934166

Cc1nc2cc(NC(=O)c3ccc(-c4ccc(F)cc4)nc3)ccc2s1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 0.70
PTPN11 Q06124 2/20 0.59
PTPN1 P18031 1/20 0.59
PTPN6 P29350 1/20 0.59
MCHR1 Q99705 4/20 0.58
HTR2C P28335 2/20 0.58
LMNA P02545 1/20 0.54
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
MEN1 O00255 1/20 0.53
MAPK1 P28482 1/20 0.53
KMT2A Q03164 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934339 0.92 TRPV1 (0.62) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL5934252 0.89 TRPV1 (0.65) TRPV1PTPN1MCHR1HTR2CLMNA
SCHEMBL5934938 0.89 TRPV1 (0.57) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL5934320 0.88 TRPV1 (0.58) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL5934580 0.84 TRPV1 (0.59) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL5934085 0.84 TRPV1 (0.54) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL5934584 0.84 TRPV1 (0.58) TRPV1LMNARAB9ANPC1TDP1
SCHEMBL5934462 0.82 TRPV1 (0.54) TRPV1MCHR1HTR2CLMNARAB9A
SCHEMBL4388633 0.82 TRPV1 (1.00) TRPV1LMNARAB9ANPC1TDP1
SCHEMBL29386356 0.82 TRPV1 (1.00) TRPV1LMNARAB9ANPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 TRPV1 53/4885PTPN11 2610/4885PTPN1 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.